Based in our Edinburgh office, David is responsible for new Private Equity investments in Scotland and also supports a number of companies in the Maven portfolio.
He started his career as a scientist with GlaxoSmithKline and then as a clinical pharmacist at Guy’s/St Thomas’ hospitals, London. After completing his PhD, he moved to international consultancy firm Wood Mackenzie (and then parent Deutsche Bank) where he supported the healthcare banking team, advising clients on their corporate and licensing strategies and performing due diligence projects on companies, products and technologies.
Most recently at ITI Life Sciences, a unique state-supported innovation fund, David was responsible for identifying funding opportunities and crafting these into significant collaborative R&D programmes. David joined Aberdeen Asset Management in September 2007, as Fund Manager for the White Rose Technology Seedcorn Fund, an early stage seed fund investing in new technology emerging from the universities of Leeds, Sheffield and York.
David has a First Class Honours degree in Pharmacy, a PhD (Molecular Biology/Gene Delivery) from the University of Bath and a MBA with distinction from Edinburgh University.